The Lynx Group
Cholangiocarcinoma News

Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma

June/July 2021, Vol 2, No 2

Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.

Look for the next issue of CCA News for additional key presentations from the CCF meeting.

Several CCA driver genes and actionable targets are being identified and are in various stages of clinical development. To date, isocitrate dehydrogenase (IDH) and fibroblast growth factor receptor 2 (FGFR2) are the best understood molecular targets in CCA.

Dr Abou-Alfa focused on data about FGFR alterations in CCA. Currently, he noted, 2 FGFR2 inhibitors have been approved by the FDA—pemigatinib (Pemazyre) and infigratinib (Truseltiq), and other agents are being investigated in CCA. In addition, in April 2021, the FDA granted a breakthrough therapy for futibatinib; and derazantinib is another investigational agent.

Dr Abou-Alfa discussed results of a final analysis of a phase 2 clinical trial of infigratinib in 108 patients with advanced or metastatic CCA and FGFR2 alterations whose disease progressed during ≥1 lines of systemic therapies. At a median follow-up of 11.3 months, infigratinib therapy led to an objective response rate (ORR) of 23%; the median progression-free survival (PFS) was 7.3 months, and the median overall survival (OS) was 12.2 months.1

Pemigatinib received FDA approval based on results from a phase 2 clinical trial in patients with advanced, unresectable CCA and FGFR2 fusion or other alteration; treatment with pemigatinib yielded an ORR of 35% and a median OS of 21.1 months.

And in a first-in-human phase 1 dose-escalation clinical trial, futibatinib showed robust response in patients with heavily pretreated advanced solid tumors.2

Other FGFR inhibitors showing promising activity in biliary tract cancers are derazantinib and Debio 1347.3,4 Polyclonal secondary FGFR2 mutations were reported to drive acquired resistance to FGFR2 inhibition in CCA.5 Several phase 3 clinical trials investigating these FGFR inhibitors are ongoing; however, accrual of patients is challenging. Dr Abou-Alfa noted that the PFS and duration of response may be more realistic end points than OS in these investigations.

Finally, IDH1 mutations represent the most common targetable driver alterations in CCA, particularly in intrahepatic CCA, which accounts for 20% of CCA cases.6 IDH1-mutated CCA is characterized by poor differentiation, dysregulation of hypermethylation, and has poor prognosis.7

IDH1-targeted small-molecule inhibitors have completed pivotal studies and exhibit promising benefits. In the double-blind, placebo-controlled phase 3 ClarIDHy study, the IDH1 inhibitor ivosidenib (Tibsovo) led to modest, but significant, PFS improvement in patients with CCA (hazard ratio, 0.37).8 A high proportion of crossover masked the significant OS benefit, but a trend for OS benefit was observed.8

Mechanisms of primary and acquired resistance are poorly understood thus far. Future research efforts need to focus on identifying patient subsets who benefit from IDH inhibitors.


  1. Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J Clin Oncol. 2021;39(3_suppl):Abstract 265.
  2. Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020;31:1405-1412.
  3. Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165-171.
  4. Voss MH, Hierro C, Heist RS, et al. A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations. Clin Cancer Res. 2019;25:2699-2707.
  5. Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion–positive cholangiocarcinoma. Cancer Discov. 2017;7:252-263.
  6. Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122:3838-3847.
  7. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552-1558.
  8. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796-807. Erratum in: Lancet Oncol. 2020;21:e462.

Related Items

Phase 1 Results of Gunagratinib in Patients with Advanced Solid Tumors Harboring FGFR Pathway Alterations
2021 Year in Review: Cholangiocarcinoma
A phase 1/2a, first-in-human clinical study demonstrated that the highly selective, irreversible pan-FGFR inhibitor gunagratinib was safe and well-tolerated in patients with advanced solid tumors, including CCA.
Prognostic Value of FGFR2 Alterations in Patients Receiving Systemic Chemotherapy for Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis indicated the prognostic value of FGFR2 fusions/rearrangements in patients with intrahepatic CCA receiving systemic chemotherapy, which warrants additional study.
FGFR2 Fusion and/or Rearrangement Profiling in Chinese Patients with Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Epidemiologic data assessed the incidence rate of FGFR2 gene fusion or rearrangement in Chinese patients with intrahepatic CCA, including those with heterogeneous FGFR2 partner genes.
A Comprehensive Genomic and Immune Profiling Study of IDH1- and IDH2-Driven Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
A comprehensive genomic and immune characterization of IDH-mutated and wild-type intrahepatic CCA revealed significant differences in genetic alterations.
Characteristics of IDH Mutations in Bile Duct Carcinoma in a Chinese Population
2021 Year in Review: Cholangiocarcinoma
A retrospective analysis in a large Chinese patient cohort with bile duct carcinoma indicated that activating IDH1/2 mutations occurred at a lower rate compared with that previously reported in the global population.
Silmitasertib (CX-4945) plus Gemcitabine and Cisplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic CCA
2021 Year in Review: Cholangiocarcinoma
Preliminary evidence suggests that combination treatment with silmitasertib plus gemcitabine/cisplatin as first-line therapy has promising efficacy and a favorable safety profile in patients with locally advanced or metastatic CCA.
Targeted Therapies in CCA: Assessment of US Oncologist Practice Patterns
2021 Year in Review: Cholangiocarcinoma
Findings from a clinical practice assessment identified gaps in knowledge, competence, and confidence regarding testing and the use of targeted therapies in patients with unresectable CCA, underscoring the important role of education in overcoming these gaps.
First-Line Toripalimab plus Lenvatinib in Combination with GemOx Chemotherapy for Advanced Intrahepatic CCA
2021 Year in Review: Cholangiocarcinoma
Results of a phase 2 study indicate that toripalimab and lenvatinib in combination with GemOx chemotherapy provide antitumor activity and reasonable tolerability in patients with advanced intrahepatic CCA.
Comparative Landscape of Actionable Somatic Alterations in Advanced CCA from Circulating Tumor and Tissue-Based DNA Profiling
2021 Year in Review: Cholangiocarcinoma
Findings from a retrospective analysis support the use of both tissue and liquid biopsy biomarker testing to guide therapy selection in patients with advanced CCA, particularly when tissue may not be readily available.
Tibsovo (Ivosidenib) FDA Approved for Advanced or Metastatic Cholangiocarcinoma and IDH1 Mutation
By Loretta Fala
2021 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma (CCA) is an aggressive cancer of the bile duct that forms inside the liver (ie, intrahepatic) or outside the liver (ie, extrahepatic, including perihilar and distal tumors). Individuals with colitis or certain liver diseases may have an increased risk for CCA. Although the precise incidence of CCA is unknown, an estimated 8000 new cases of CCA are diagnosed annually in the United States. It is likely, however, that this number is higher, because CCA is difficult to diagnose and may be misclassified at times.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: